SCHEMBL2462033

SCHEMBL2462033

O=C(NC(c1cccc(OCc2ccccc2)c1)c1nccnc1Cl)C1CCCC1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 2/20 0.46
F10 P00742 3/20 0.44
POLB P06746 1/20 0.44
DRD2 P14416 1/20 0.44
KMT2A Q03164 2/20 0.43
SMN1; SMN2 Q16637 1/20 0.43
PDE4A P27815 1/20 0.42
PDE4B Q07343 1/20 0.42
PDE4C Q08493 1/20 0.42
PDE4D Q08499 1/20 0.42
CHRM3 P20309 2/20 0.42
KDM4E B2RXH2 1/20 0.42
SPHK1 Q9NYA1 1/20 0.41
PTPN1 P18031 1/20 0.41
MEN1 O00255 1/20 0.41
NPC1 O15118 1/20 0.41
HTT P42858 1/20 0.41
RAB9A P51151 1/20 0.41
JAK2 O60674 1/20 0.41
JAK1 P23458 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2462459 0.99 LMNA (0.46) LMNAF10POLBDRD2KMT2A
SCHEMBL2462310 0.99 LMNA (0.46) LMNAF10POLBDRD2KMT2A
SCHEMBL2463303 0.99 LMNA (0.45) LMNAF10POLBDRD2KMT2A
SCHEMBL2461530 0.91 DRD2 (0.45) F10POLBDRD2KMT2ASMN1; SMN2
SCHEMBL2462607 0.91 DRD2 (0.45) F10POLBDRD2KMT2ASMN1; SMN2
SCHEMBL2461533 0.91 DRD2 (0.45) F10POLBDRD2KMT2ASMN1; SMN2
SCHEMBL2463258 0.90 DRD2 (0.50) LMNAF10DRD2SMN1; SMN2CHRM3
SCHEMBL2460309 0.90 DRD2 (0.44) F10POLBDRD2KMT2ASMN1; SMN2
SCHEMBL2459300 0.90 KMT2A (0.42) F10DRD2KMT2ASMN1; SMN2PDE4A
SCHEMBL2460567 0.89 KMT2A (0.41) F10DRD2KMT2ASMN1; SMN2CHRM3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1675860-B1 IMIDAZO[1,5-A]PYRAZINES AS TYROSINE KINASE INHIBITORS OSI PHARM INC (US) 2011-09-21 EP disclosed
US-20090181940-A1 Imidazopyrazine Tyrosine Kinase Inhibitors OSI PHARMACEUTICALS, INC. 2009-07-16 US disclosed
US-7459554-B2 Imidazopyrazine tyrosine kinase inhibitors OSI PHARMACEUTICALS, INC. (US) 2008-12-02 US disclosed
US-20080227788-A9 IMIDAZOPYRAZINE TYROSINE KINASE INHIBITORS BECK PATRICIA A 2008-09-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080227788-A9 IMIDAZOPYRAZINE TYROSINE KINASE INHIBITORS IGF1R, IRS1, IGFBP1 LMNA 3821/4885F10 3668/4885POLB 2879/4885
US-20090181940-A1 Imidazopyrazine Tyrosine Kinase Inhibitors IGF1R, IRS1, IGFBP1 LMNA 3821/4885F10 3668/4885POLB 2879/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.